MC2 Therapeutics aims to lead psoriasis market
Psoriasis drug Wynzora brings MC2 Therapeutics one step closer to achieving its goal of becoming world-leading within drugs applied onto skin, says MC2 Therapeutics CEO Jesper Lange.
BY ANDREAS LØNSTRUP, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company MC2, which is owned by family members behind major Danish companies Danfoss and Radiometer, dreams of becoming world-leading in drugs applied to the skin. The first step towards reaching this goal includes psoriasis drug Wynzora, which has been approved by the US Food and Drug Administration and is being launched in the US, and which awaits Europe approval in summer, according to Danish newspaper Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
